A Promising Potential Drug Target: KLHL30, a Kelch-Like 30 Molecule in the KLH Family

Target Name: KLHL30

NCBI ID: G377007

KLHL30

A Promising Potential Drug Target: KLHL30, a Kelch-Like 30 Molecule in the KLH Family

Introduction

Kelch-like 30 (KLHL30) is a protein that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, which resembles that of Kelch proteins, makes it an attractive target for small molecules and antibodies. In this article, we will discuss the KLHL30 protein, its potential drug targets, and its current research status.

Structure and Function

KLHL30 is a 22-kDa protein that belongs to the Kelch family of proteins. This family is characterized by the presence of a unique disulfide bond, which is a covalent bond formed by the fusion of two amino acids. KLHL30 has four conserved domains: a N-terminal Kelch domain, a catalytic domain, a transmembrane region, and a C-terminal T-cell receptor (TCR) domain.

The KLHL30 protein has a unique feature, which is a stretch of 30 amino acids that is rich in acidic and basic residues. This stretch is known as the "Kelch-like region" (KLR) and is the source of the protein's name . The KLR is involved in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions.

KLHL30 functions as a negative regulator of the T-cell receptor (TCR), which is a key transcription factor that plays a crucial role in the development and regulation of T-cells. The TCR is responsible for recognizing and responding to foreign antigens, which are essential for immune surveillance. However, over-expression of the TCR can lead to autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

KLHL30 has been shown to regulate the activity of the TCR in various ways. For instance, it can inhibit the TCR-CD28 interaction, which is critical for the activation of T cells. Additionally, KLHL30 can enhance the negative regulation of the TCR by binding to the co-factor PDGF-1, which is a critical regulator of T-cell growth and differentiation.

Potential Drug Targets

KLHL30 is a potential drug target due to its unique structure and its involvement in various cellular processes. Several studies have identified potential small molecules and antibodies that can interact with KLHL30 and modulate its activity.

One of the most promising potential drug targets for KLHL30 is the small molecule drug, in-30 (MK-30), which is a in-like protein that can interact with KLHL30 and inhibit its activity. MK-30 is a potent inhibitor of the TCR and has been shown to be effective in treating various autoimmune diseases.

Another potential drug target for KLHL30 is the antibody, monoclonal antibody (mAb) 5H12, which recognizes a specific epitope (epitope refers to a portion of the protein that is recognized by an antibody). mAb 5H12 can interact with KLHL30 and enhance its negative regulation of the TCR.

KLHL30 has also been shown to interact with several other proteins, including the transcription factor, p300, and the protein, nuclear factor of activated T cells (NFAT). These interactions may have implications for the regulation of various cellular processes and could be potential drug targets in the future.

Current Research

KLHL30 is a promising drug target due to its unique structure and its involvement in various cellular processes. Several studies have identified potential small molecules and antibodies that can interact with KLHL30 and modulate its activity.

One of the most promising potential drug targets for KLHL30 is the small molecule drug, MK-30, which is a in-like protein that can interact with KLHL30 and inhibit its activity. MK-30 has been shown to be effective in treating various autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Another potential drug target for KLHL30 is the antibody, mAb 5H12, which recognizes a specific epitope on KLHL30 and enhances its negative regulation of the TCR.

KLHL30 has also been shown to interact with several other proteins, including the transcription factor, p300, and the protein,

Protein Name: Kelch Like Family Member 30

The "KLHL30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets